Table 1.
Characteristics of HIV-infected patients who completed isoniazid preventive therapy vs. HIV-infected patients who did not complete isoniazid preventive therapy in the 29 TB/HIV in Rio clinics, post-HIV/tuberculosis training (n = 1455).
| Completed IPT (n = 1230) | Did not complete IPT (225) | P-value | |
|---|---|---|---|
| Male | 742 (85%) | 133 (15%) | 0.73 |
| Female | 488 (84%) | 92 (16%) | |
| Median age (IQR) | 42 (34, 49) | 39 (32, 47) | 0.01 |
| Median CD4 cell count (IQR) | 527 (368, 729) | 491 (306, 710) | <0.03 |
| Receiving HAART at time of IPT | 846 (87%) | 125 (13%) | <0.01 |
| Not receiving HAART at time of IPT | 384 (79%) | 100 (21%) | |
| Mean time on HAART (months) | 52.5 | 50.5 | 0.55 |
| Median (IQR) time on HAART (months) | 49 (25, 78) | 42 (18, 74) | 0.39 |
IPT, isoniazid preventive therapy; IQR, interquartile range.